PHESGO 1200MG/600MG/30.000 UNITS S.C. SOL. FOR INJ. 15 ML

Indications: 1-Early Breast Cancer. PHESGO� (pertuzumab trastuzumab and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for **the neoadjuvant treatment of adult patients with HER2-positive locally advanced inflammatory or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC). **the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence. 2-Metastatic Breast Cancer. PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.